Australia
Industry
BMI View: The withdrawal of the Blackmores-Pharmacy Guild of Australia deal highlights that the needs and interests of various stakeholders has to be appreciated. We believe that...
2011-10-07Industry
BMI View: The Blackmores and Pharmacy Guild of Australia agreement will be cancelled or rendered ineffective if it continues to be met with strong resistance from healthcare professionals,...
2011-10-04Industry
BMI View: The unpopularity of the Australian government's listing of previously deferred drugs, in addition to new drug listings, has pressured the government to reinstate the previous...
2011-10-03Industry
BMI View: High generic drug prices will affect the listing of innovative drugs on Australia's Pharmaceutical Benefit Scheme (PBS) as the government is concerned about expenditure on...
2011-07-05Industry
BMI View: Australia's challenging economic situation is affecting its pharmaceutical market. Embracement of expensive patented drugs by the three main stakeholders - payers, prescribers...
2011-03-23Industry
BMI View: Australia's pharmaceutical market is increasingly rational and unlike most of those in developed economies. Medicine spending as a percentage of GDP in 2009 was 0.80%, which...
2010-12-17Industry
BMI View: The direct-to-pharmacy (DTP) distribution model will only be adopted by a few large drugmakers in a selection of concentrated pharmaceutical markets. While it is tempting...
2010-12-09Economy
Developed state underperformance remains a recurring theme within our Industry analysis. We remain concerned about US labour market weakness and its impact, particularly on consumer...
2010-09-28
